Belchamber et al. 2021

1	Altered neutrophil phenotype and function in non-ICU hospitalised COVID-19 patients
2	correlated with disease severity
3 4	
5 6 7	Belchamber KBR* ¹ , Thein OS* ¹ , Hazeldine J ² , Grudzinska FS ¹ , Hughes MJ ¹ , Jasper AE ¹ , Yip KP ¹ , Sapey E ^{1,3,4} , Parekh D ¹ , Thickett DR ^{#1} , Scott A ^{#1} .
, 8 9	*joint first author # joint senior author
10	¹ Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University
11	of Birmingham, B15 2TT, UK
12	² National Institute for Health Research Surgical Reconstruction and Microbiology Research
13	Centre, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, United
14	Kingdom.
15	³ PIONEER HDR-UK Hub in acute care, Institute of Inflammation and Ageing, University
16	of Birmingham, B15 2TT, UK
17	⁴ NIHR Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust,
18	Edgbaston, Birmingham, B12 2GW
19	
20	Corresponding author:
21	Professor David Thickett, Institute of Inflammation and Ageing, University of Birmingham,
22	Birmingham B15 2TH, UK; d.thickett@bham.ac.uk. <u>+44 (0)121 371 3257</u>
23	
24	Author contributions: Concept and design: KBRB, OST, JH, ES, DP, DRT, AS. Neutrophil work:
25	KBRB, OST. Patient recruitment: OST, FSG, KPY. Additional laboratory work: MJH, AEJ, AS.
26	Drafting manuscript: KBRB, OST, ES, DP, DRT, AS. All authors have read and approved the
27	manuscript.
28	
29	This article has an online supplement.
30	
31	Sources of funding: OST/DT/DP; Birmingham Health partners, KBRB/ES; Alpha One
32	Foundation (617303), JH; National Institute for Health Research (NIHR) Surgical
33	Reconstruction and Microbiology Research Centre, ES/KYP; British Lung Foundation
34	(PPRG16), DT/AS/ES/FSG; Dunhill trust (RTF1906\86), ES; Health Data Research-UK, DT/DP; NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Belchamber et al. 2021

- 35 Health Technology Assessment, DT/AS/ES; Health Technology Assessment (NIHR129593),
- 36 DT/AS/ES; Medical Research Council (MR/L002736/1).

Belchamber et al. 2021

38

- 39 Abstract word count: 250
- 40 **Total word count:** 3188
- 41 Abstract

Rational: Infection with the SARS-CoV2 virus is associated with elevated neutrophil counts.
Evidence of neutrophil dysfunction in COVID-19 is based predominantly on transcriptomics
or single functional assays. Cell functions are interwoven pathways, and so understanding
the effect of COVID-19 across the spectrum of neutrophil function may identify tractable
therapeutic targets.

47

48 **Objectives:** Examine neutrophil phenotype and functional capacity in COVID-19 patients
 49 versus age-matched controls (AMC)

- 50
- 51 **Methods:** Isolated neutrophils from 41 hospitalised, non-ICU COVID-19 patients and 23
- 52 AMC underwent *ex vivo* analyses for migration, bacterial phagocytosis, ROS generation, NET
- 53 formation (NETosis) and cell surface receptor expression. DNAse 1 activity was measured,
- alongside circulating levels of cfDNA, MPO, VEGF, IL-6 and sTNFRI. All measurements were
- 55 correlated to clinical outcome. Serial sampling on day 3-5 post hospitalisation were also
- 56 measured.57
- 58 **Results:** Compared to AMC, COVID-19 neutrophils demonstrated elevated transmigration
- 59 (p=0.0397) and NETosis (p=0.0366), but impaired phagocytosis (p=0.0236) associated with
- 60 impaired ROS generation (p<0.0001). Surface expression of CD54 (p<0.0001) and CD11c
- 61 (p=0.0008) was significantly increased and CD11b significantly decreased (p=0.0229) on
- 62 COVID-19 patient neutrophils. COVID-19 patients showed increased systemic markers of
- 63 NETosis including increased cfDNA (p=0.0153) and impaired DNAse activity (p<0.0.001).
- 64 MPO (p<0.0001), VEGF (p<0.0001), TNFRI (p<0.0001) and IL-6 (p=0.009) were elevated in
- 65 COVID-19, which positively correlated with disease severity by 4C score.
- 66

67 **Conclusion:** COVID-19 is associated with neutrophil dysfunction across all main effector

- 68 functions, with altered phenotype, elevated migration, impaired antimicrobial responses
- 69 and elevated NETosis. These changes represent a clear mechanism for tissue damage and
- 70 highlight that targeting neutrophil function may help modulate COVID-19 severity.
- 71

Belchamber et al. 2021

72 Introduction

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) virus, was declared a global pandemic by The World Health Organisation on 11th March 2020 [1]. Up to 80% of people infected with SARS-CoV2 experience mild to moderate respiratory disease, but in 10-20% of cases, infection can manifest as pneumonitis, with 5% progressing to acute respiratory distress syndrome (ARDS). The overall worldwide mortality rate is 2.2% but this increases to up to 50% in the presence of ARDS [2].

80

Dysregulated virus induced host-immune responses are thought to be the primary cause of severe COVID-19 [3]. Neutrophils are frontline effector cells that protect against rapidly dividing pathogens and play a pivotal role in the antiviral immune response [4]. Early during an inflammatory event, neutrophils migrate into lung tissue where they perform phagocytosis and release proteases, reactive oxygen species (ROS) and as a later response, neutrophil extracellular traps (NETs) to aid clearance of infection [5].

87

88 Advanced age is a recognised risk factor for severe COVID-19, including the development of 89 ARDS [6-8]. Ageing is associated with changes in neutrophil function, including reduced 90 migratory accuracy [9], phagocytosis [10] and NETosis [11], which may delay pathogen 91 clearance and increase bystander tissue injury. Further impairments in neutrophil function 92 have been observed in patients with pneumonia [12], sepsis [13] and ARDS [14]. This 93 dysfunction is most apparent in older adults with severe infections [15] and is associated with 94 poor clinical outcomes [12, 13]. Importantly, these functional deficits appear amenable to 95 therapeutic correction, especially in early or less severe infective episodes, suggesting that 96 neutrophils, or their products, may form a tractable target in inflammatory disease [16, 17]. 97 There is some evidence that neutrophil dysfunction could be associated with distinct cellular 98 phenotypes within the neutrophil population, with immature, senescent, activated and pro-99 inflammatory neutrophils identified in age and disease [13, 18, 19].

100

Emerging studies suggest that neutrophils are implicated in the pathogenesis of severe COVID-19 and every reporting study has described cell dysfunction (or inferred cell dysfunction through transcriptomics) which could contribute to tissue damage and secondary infection [20-27] However, studies have often been small, fail to provide age-matched controls, assess patients on the intensive care unit (ICU) after a considerable delay since symptom onset, and often consider neutrophil functions in isolation.

107

108 These are important considerations. As neutrophil functions change with age, age matched 109 controls are important to identify pathological differences. Although approximately 12% of hospitalised COVID-19 require ICU support, the majority of hospital admissions and deaths 110 111 occur on non-ICU wards [28]; understanding how to improve outcomes for this patient group 112 is vital. Most studies in sepsis have demonstrated cell function is more therapeutically 113 tractable during early disease (before ICU care is needed), so the timeliness of intervention is 114 important. Cell functions are enabled by interwoven cell pathways with important differences 115 in internal signalling; knowing which functions are impaired informs which therapeutic 116 strategies might restore/maintain all facets of cellular function. 117

Belchamber et al. 2021

119

120 We hypothesised that neutrophils from COVID-19 patients would exhibit diverse altered 121 effector functions and changes to phenotype, with the degree of dysfunction associated with 122 adverse patient outcomes.

123

124 This study aimed to perform, for the first time, a comprehensive assessment of *ex vivo* 125 neutrophil phenotype and function in a statistically powered cohort of hospitalised, non-ICU 126 SARS-CoV2 infected patients compared to aged-matched controls and investigate 127 relationships with clinical outcomes.

128 129 **Methods**

130 Healthy donor and patient recruitment

Recruitment is summarised in Figure 1. COVID-19 patients were recruited January to March 2021 from the Queen Elizabeth Hospital Birmingham, in accordance with ethics REC ref: 13/WA/0299 and 20/WA/0092 approved by the West Midlands – Solihull research ethics committee. Written informed consent was obtained where possible; patients unable to consent due to lack of capacity were consented by proxy; designated consultee via telephone or professional consultee. Follow-up samples were collected at days 3-5 with confirmed consent, where possible.

138

139 Patients were recruited within 48 hours of hospital admission due to pneumonitis/pneumonia 140 related to COVID-19. All patients had a positive COVID-19 PCR swab. No patients received 141 novel treatments or were part of a COVID clinical medicinal trial on recruitment to this study. 142 Exclusion criteria were admission outside timeframe, no evidence of 143 pneumonia/pneumonitis, long-term oral steroid use, haematological malignancy causing 144 neutropenia, any cause of immunosuppression, recruitment into a trial for novel therapy, 145 admission to ITU, palliative or imminent treatment withdrawal within 24 hours and 146 pregnancy. Patients with COPD or asthma were excluded due to known alterations in 147 neutrophil function in these patient groups [29]. COVID-19 patients were stratified using the 148 4C Mortality Score for COVID-19, separated by scores <9 and >=9 (in-hospital mortality <9.9% 149 and >31.4% respectively) [30]. Patients were classified with ARDS based on the Berlin criteria; 150 SpO₂: FiO₂ ratio (SF), converted to PaO2: FiO2 (PF) (SF=57-0.61PF).

151

Age matched controls (AMC) were either recruited from patients attending pre-booked faceto-face outpatient appointments or from hospital staff. AMC had no evidence of acute illness

- including COVID-19 within the last two weeks, as assessed by a respiratory physician, and metthe other exclusion criteria described above.
- 156

Additional details on methodology are provided in the online supplement. These methods include; plasma collection, neutrophil isolation by Pecoll gradient centrifugation, phagocytosis of fluorescent *S. pneumoniae*, NETosis by release of cell-free (cf)DNA, transwell migration, phenotyping by flow cytometry, serum DNase-1 activity assay, plasma cfDNA quantification citrullinated bistope H2 detection and plasma biomarker quantification

161 quantification, citrullinated histone H3 detection and plasma biomarker quantification.

162

163 Statistics

164 Statistical analysis is described in the online supplement. A power calculation performed on

165 isolated neutrophil NETosis data (80%, alpha 0.05) suggested 18 participants were required

Belchamber et al. 2021

in each group (see supplement for details). Data are presented throughout as median (IQR),with each n number representing a separate study participant. Significance was defined at p

168 <0.05. There were no corrections for multiple comparisons but exact p values are given.

- 169
- 170
- 171 Results
- 172

173 Clinical characterisation

174 41 COVID-19 patients (mean age 69.9 years) and 23 healthy AMC (mean age 69.7 years) were 175 included in the study. Demographics are provided in Table 1. COVID-19 patients were 176 admitted to hospital 7 days (range 3-14) after symptom onset and were recruited to the study 177 after median 2 days (range 1-2). Length of hospital stay was 7.7 days (survivors 7.5 days, non-178 survivors 9.1 days) and the mortality rate was 24% (10/41). 38/41 patients received 179 dexamethasone as part of their acute treatment as per standard of care [31]. 17/41 patients 180 had ARDS as defined by the Berlin criteria with the exception of ventilation pressure [32], and 181 of these 8 had moderate to severe ARDS.

182

183 Neutrophil migration is elevated through a transwell system in COVID-19

Neutrophils from COVID-19 patients demonstrated increased transwell migration towards CXCL-8 compared to AMC (Fold change of neutrophils migrated to CXCL-8 vs. vehicle control: 12.15 (51.4) AMC vs. 40.63 (115.2) COVID-19, p=0.0397, Figure 2A). Migration was not associated with 4C score (p=0.5575, Supplementary Figure 5A), or survival at 28 days (p=0.2563, Supplementary Figure 6A). There was no change in migration at follow up (p=0.1641, Supplementary Figure 4A).

190

191 Neutrophil phagocytosis is impaired in COVID-19

Neutrophil phagocytosis of *S. pneumoniae* was significantly decreased in COVID-19 patients
compared to AMC (Median fluorescence intensity (MFI): 8.0 (4.2) AMC vs. 6.6 (2.6) COVID-19,
p<0.0236, Figure 2B). Phagocytosis was not associated with 4C score (p=0.3257,
Supplementary Figure 5B) or survival at 28 days (p=0.9228, Supplementary Figure 6B). There
were no differences in neutrophil viability between patient groups or treatment conditions
(p=0.6726, Supplementary Figure 3A).

198

199 Neutrophil derived ROS generation following phagocytosis is impaired in COVID-19

200 Cytoplasmic (c)ROS, and nuclear/mitochondrial (n/m)ROS were measured in resting 201 neutrophils and following phagocytosis. Compared to unstimulated cells, cROS levels were 202 elevated after phagocytosis in both AMC (MFI: 46.8 (28) baseline vs. 64.9 (51) 30 minutes, 203 p<0.0005) and COVID-19 patients (MFI: 44.1 (35) baseline vs. 65.3 (60) 30 minutes, p=0.0235). 204 However, no differences were observed in cROS levels in either resting (p=0.999) or 205 stimulated (p=0.3946) neutrophils between study groups (Figure 2C).

206

207 Compared to resting neutrophils, n/mROS levels were significantly higher after phagocytosis

in neutrophils isolated from AMC (MFI: 21.8 (21) baseline vs. 32.0 (38), p<0.0001), but not in

209 COVID-19 patients (MFI: 18.9 (12) baseline vs. 21.2 (12), p=0.0610). No significant differences 210 were found in the levels of n/mROS in resting neutrophils (MFI: 21.8 (21) AMC vs. 18.9 (12)

were found in the levels of n/mROS in resting neutrophils (MFI: 21.8 (21) AMC vs. 18.9 (12) COVID-19, p=0.0610). However, reduced levels of n/mROS were measured in neutrophils

Belchamber et al. 2021

7

isolated from COVID-19 patients following phagocytosis when compared to AMC (MFI: 32.0
(38) AMC vs. 21.2 (12) COVID-19, p<0.0001, Figure 2D).

214

215 Neutrophil NETosis is elevated in COVID-19

Higher levels of cfDNA were detected in supernatants obtained from COVID-19 patient neutrophils post-PMA treatment compared to AMC (fold change in absorbance of neutrophils

218 stimulated with PMA vs. vehicle control: 1.29 (0.32) AMC vs. 1.53 (1.66) COVID-19, p=0.0366,

- 219 Figure 3A). There were no differences in resting neutrophils NET production between COVID
- 220 patients and AMC (Supplementary Figure S3). When COVID-19 patients were stratified by
- disease severity, more severe disease was associated with increased NETosis (fold change:
- 222 1.17 (0.35) Low 4C vs. 1.41 (0.80) High 4C, p=0.0118, Figure 3B.
- 223

At hospital admission, COVID-19 patients presented with higher concentrations of plasma cfDNA compared to AMC (621ng/ml (1324) AMC vs. 1071ng/ml (856) COVID-19, p=0.0153, Figure3C), which persisted at Day 3-5 day (p=0.0186, Figure. 3D).

227

To determine whether neutrophils, via NETosis, were a source of the cfDNA, plasma samples
were screened for the presence of CitH3, a protein that decorates the DNA backbone of NETs
[33]. Western blotting revealed the presence of CitH3 in 6 out of 8 samples analysed (75%,

- 231 Supplementary Figure 7).
- 232

Using NETs as a substrate, serum DNase activity was lower in COVID-19 patients at the time of hospital admission when compared to AMCs (% degradation: 88.4% (93) AMC vs. 12.8% (49), p<0.0001, Figure 3E).

236

237 Neutrophil phenotype is altered in COVID-19

To determine whether changes observed in neutrophil function were associated with
phenotype, surface expression of key surface molecules were investigated by flow cytometry.
A table of percentage receptor expression and MFI is shown in table 2.

241

Both the percentage of neutrophils expressing the activation marker CD11b (81% (8.9) AMC
vs. 67.8% (43.9) COVID-19, p=0.0229), and its surface expression (MFI:343 (119) AMC vs. 40
(141) COVID-19, p=0.0003, Figure 4A) were reduced in COVID-19 patients. Expression of the
adhesion molecule CD11c was also elevated in COVID-19 patients (MFI: 220 (1274) AMC vs.
1148 (670) COVID-19, p<0.0008, Figure 4B).

247

Both the percentage of neutrophils expressing CD54, a marker of reverse transmigration (33.4% (35.3) AMC vs. 71.3% (21.2) COVID-19, p<0.0001, Figure 4C) and its surface expression (MFI: 21 (38) AMC vs. 73 (58) COVID-19, p=0.0008 Figure 4D) were elevated in COVID-19 patients.

252

Expression of CD66b, CD62L, CD10, CXCR2, CXCR4 and PD-L1 did not differ between AMC and
 COVID-19 patients (see table 2). There was no association of neutrophil phenotypic marker
 expression with 4C severity score, or in survivors and non-survivors.

256

On day 3-5 follow-up, relative to baseline readings, there was a decrease in CXCR2 expression (MFI: 1960 (1601) Day 1 vs. 1126 (1262) Day 3-5, p=0.0322, Figure 4E) and a significant

Belchamber et al. 2021

increase in CXCR4 expression (MFI: 1785 (3951) Day 1 vs. 10248 (16483) Day 3-5, p=0.0273,
 Figure 4F). The percentage of cells expressing CD54 was significantly reduced at 3-5 day follow
 up (80.6% (34.6) Day 1 vs. 58.9% (38.3) Day 3-5, p=0.0420, Figure 4G)

262

264

263 Systemic inflammatory mediators are elevated in COVID-19

COVID-19 patients showed elevated levels of IL-6 (p<0.009, Figure 5A), VEGF (p<0.0001, Figure5B), sTNFRI (p<0.0001, Figure 5C), and MPO (p<0.0001, Figure 5D), but not GM-CSF (p=0.3375, Figure 5E) when compared to AMC.

268

Only 2/41 COVID-19 patients demonstrated a hyperinflammatory phenotype when stratified
 using the algorithm developed to classify non-COVID ARDS phenotypes[34].

271

IL-6 and sTNFRI concentrations were higher in non-survivors versus survivors (p=0.0027, p=0.0420 respectively, Supplementary Figure. 6) and raised in those patients with a 4C score
 >= 9 (IL-6 p=0.0059, sTNFRI p=0.0478, Supplementary Figure. 5).

275

IL-6 levels were significantly raised in patients with moderate to severe ARDS compared to
 mild (p=0.0468, Supplementary Figure. 6). We observed no associations between the severity
 of ARDS and VEGF (p=0.1164) or sTNFRI (p=0.3953).

279

280

281 Discussion

282 We present novel findings of COVID-associated neutrophil dysfunction, across all main 283 effector functions. In summary, compared to AMC, systemic neutrophils from patients 284 hospitalised with moderate severity COVID-19 demonstrated increased migration, impaired 285 anti-microbial responses including reduced phagocytosis and nuclear/mitochondrial ROS 286 generation after phagocytosis. Later/end phase neutrophil responses were increased, namely 287 ex- vivo NETosis with evidence of increased systemic NETosis, coupled with reduced DNase 288 activity. We also show an altered but distinct neutrophil phenotype, not compatible with a 289 purely activated, immature, senescent or anti-inflammatory phenotype as described before 290 (summarised in Figure 6). Our data suggests the energetics of the cells were not overtly 291 compromised, as some "high energy-consuming" functions (such as migration [35]) were 292 elevated. Of note, some of these changes have been described by authors studying COVID-19 293 before the widespread use of dexamethasone as standard of care [27, 36], suggesting our 294 results are not a treatment effect.

295

Individually, as described in other studies, these changes to effector function could
compromise aspects of host defence. Collectively, these changes represent a clear
mechanism for significant tissue damage. Poor phagocytosis would impede pathogen
clearance, increasing the likelihood of secondary infection and amplifying inflammation.
NETosis is implicated in tissue damage and thrombotic events in several disease settings [37,
38]. The inability to clear NETs through reduced DNAse activity would further augment
NETosis-associated tissue damage [39].

Belchamber et al. 2021

9

Secondary infection in COVID-19 is associated with increased severity of lung disease and poorer outcomes [40, 41]. Impaired neutrophil antimicrobial responses towards *S. pneumoniae*, the most common bacteria implicated in secondary infection in COVID-19 [42], alongside impaired intracellular ROS generation important for phagosomal bacterial killing [43], may contribute to the incidence of secondary infection and poorer outcomes for these patients.

310

Elevated NETosis [23, 24, 44] and increased systemic concentrations of cfDNA [23, 24] have been described previously in small numbers of COVID-19 patients. Our observation of reduced serum DNase activity builds on studies showing reduced plasma concentrations of Gelosin in COVID-19; Gelosin depolymerises filamentous actin, an inhibitor of DNAse activity [45-47]. Thus, a circulating microenvironment dominated by negative regulators of DNase-1 could offer a potential mechanistic explanation for the impaired DNase-1 activity we report, with elevated NETosis contributing to host tissue damage and thrombotic events.

318

319 The collective pattern of neutrophil dysfunction in COVID-19 speaks of alterations to 320 mechanosensing within these cells. Elevated migration and impaired phagocytosis could both 321 be linked to reduced pseudopod extrusion, which is known to increase migratory speed [48]. 322 Also, pseudopods are involved in phagocytosis, with reorganisation of the cell composition to 323 enable bacterial engulfment [49]. Phosphoinositide 3-kinase (PI3K) is a key intracellular 324 signalling molecule involved in chemotaxis, cytoskeletal rearrangement for phagocytosis, and 325 superoxide generation [50] and has most recently been implicated in NETosis [51]. Aberrant 326 PI3K signalling is linked to increasing age, and PI3K inhibitors have been show to improve 327 neutrophil migratory accuracy in the elderly [9], while reducing NET formation ex vivo [52, 328 53]. This suggests there might be tractable targets across neutrophil cellular functions, which 329 could be manipulated to enhance some responses (phagocytosis) while reducing others 330 (NETosis), and to improve innate immune responses in COVID-19.

331

332 We observed an altered neutrophil phenotype in moderate COVID-19, not compatible with 333 previously described populations. COVID-19 neutrophils expressed decreased levels of the 334 activation marker CD11b and a lack of CD62L shedding, which has previously been observed 335 in sepsis [54]. We saw elevated expression of the immunosuppressive marker CD11c, also 336 elevated in sepsis [54], but no changes in the expression of CD10; a marker of immature 337 neutrophils [55], or CXCR2 and CXCR4; markers of senescence [56]. This contrasted with 338 RNAseq studies that reported populations of immature and senescent neutrophils in severe 339 COVID-19 patients compared to mild patients or non-AMC [22, 57]. Our contrasting data from 340 moderate COVID-19 patients suggests that either the duration of COVID-19 infection or the 341 extreme severity of infection (from not requiring, to requiring organ support) affects cellular 342 dysfunction and, as in pneumonia and sepsis [17], may support a window for therapeutic 343 intervention.

344

Finally, we observed that COVID-19 neutrophils expressed elevated CD54, a marker of reverse transmigration, whereby neutrophils migrate from the tissues back into the circulation. These cells are capable of high levels of oxidative burst [58], which may contribute to high levels of NETosis. By day 3-5 post-admission, we report increased levels of senescent CXCR4⁺ CXCR2⁻ neutrophils, confirming a report of reduced CXCR2⁺ neutrophils in ICU COVID-19 patients [59].

Belchamber et al. 2021

10

351 The majority of COVID-19 hospitalisations and deaths occur in non-ICU wards [28], making 352 this cohort important for targeted intervention. While there was evidence of systemic 353 inflammation, indicated by elevated levels of circulating IL-6, sTNFRI and VEGF, less than 5% 354 of the patients in the current study met the criteria for the hyper-inflammation phenotype 355 described in ARDS [34] and had levels of circulating mediators lower than described in "usual" 356 sepsis [13]. IL-6 and CXCL-8, as well as platelet derived factors and antigen-antibody 357 complexes are thought to drive NET formation, providing another mechanism to link systemic 358 inflammation to neutrophil dysfunction [60-62].

359

360 Our data suggests a distinct cellular response in moderate COVID-19 which contribute to on-361 going immune mediated harm, but which may be modifiable using a targeted therapy given 362 administered at this crucial point in disease progression. While ex vivo experiments suggest 363 PI3K inhibition may improve all aspects of neutrophil dysfunction described in the current 364 study [52, 53], this has not tested in COVID-19 patients. The STOP-COVID trial (Superiority 365 Trial Of Protease inhibition in COVID-19, NCT04343898) is assessing the ability of Brensocatib to reduce neutrophil serine protease activity in COVID-19. Brensocatib improves clinical 366 367 outcomes in bronchiectasis patients by reducing neutrophil proteases systemically [63], and 368 may reduce the consequences of elevated NETosis in COVID-19, described in the current 369 study.

370

371 Our data complements studies which showed increased systemic NETosis in COVID-19 [24, 372 64], and elevates those which show increased NETosis in isolated neutrophils, by including 373 increased patient numbers and appropriate AMC [23, 24, 44]. A study by Masso-Silva et al. 374 recently showed elevated neutrophil phagocytosis in sixteen ICU COVID-19 patients 375 compared to non-AMC. Differing results may be due to the differing experimental techniques, 376 disease severity and patient numbers. Their study used polymorphoprep rather than Percoll® 377 to isolate neutrophils, and the authors combined data from multiple blood samples taken 378 over eleven days of hospitalisation. As we show changes in neutrophil phenotype and 379 function over the 3-5 time course of our study, we suggest that combining time points 380 obscures the complex changes occurring in this short-lived cell population. We also used 381 opsonised S. pneumoniae for phagocytosis studies, which may be phagocytosed by different 382 mechanisms to S. aureus bioparticles [49], confounding results.

- 383
- 384 Limitations

This study was limited due to the safety measures required. All experiments were carried out within a BSL2 hood and methods chosen based on tolerance to inactivation/fixation with 4% PFA. Our patients did not include an ICU group, however, mild-moderate disease forms a larger proportion of overall COVID-19 patients, and we believe it is this point in the patient pathway which holds most potential for successful intervention.

391 Conclusion

Our study shows that moderate COVID-19 is associated with alterations in neutrophil phenotype, increased migratory capacity and NETosis, and impaired antimicrobial function which contributes to the severity of COVID-19. Elevated NETosis in the lung is associated with disease severity, and elevated systemic NET production is likely to contribute to inflammation,

- which may drive ARDS associated damage, and thrombosis. Targeting neutrophils and their
- downstream effectors may be beneficial in the treatment of COVID-19.

Belchamber et al. 2021

	AMC	COVID-19	COVID-19	COVID-19	COVID-19	Survived to	Died
	N=23	N=41	4C <=8	4C ≧9	Follow up	discharge	
			N=10	N=31	N=12	N=31	N=10
Male:Female	8:15	26:15	7:3	18:12	5:7	19:12	7:3
White:non-	22:1	31:10	7:3	23:8	10:2		
white							
Died (%)	0 (0%)	10 (24%)	0 (0%)	10 (32%)	4 (33%)	0 (0%)	10 (100%)
Age	68 (61-	71 5 (58-84)	78 (69-87)	71 (58-84)**	83 (77 8-	61 (56-78)	87 (79-90)**
1.50	78)	, 1.5 (56 6 1)	/0 (05 0/)	, 1 (50 0 1)	90.0)	01 (00 70)	0, (,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BMI (kg/m2)	, 0,	26 4 (24 2-	31.26	25 39 (23 3-	24 7	297(243-	25 7 (23 8-
51111 (16/112)		32.8)	(30.0-36.9)	31 9)*	(21.8-	33 3)	28 5)
		52.0)	(30.0 30.3)	51.57	26.1)	33.57	20.57
					20.1)		
Comorbidity			- (()	- (. (- (- (().h
Cardiovascular	4 (17.4%)	12 (29.3%)	3 (30%)	9 (29.0%)	4 (33.3%)	7 (22.6%)	8 (80%)*
Respiratory	0 (0%)	1 (2.4%)	0 (0%)	1 (3.2%)	0 (0%)	2 (6.5%)	2 (20%)
Endocrine	7 (30.4%)	16 (39.0%)	3 (30%)	13 (41.9%)	5 (41.7%)	12 (38.7%)	5 (50%)
Hypertension	12	19 (46.3%)	0 (0%)	19 (61.3)**	7 (58.3%)	10 (32.2%)	9 (90%)*
	(52.2%)						
Other	11	24 (58.5%)	1 (10%)	23 (74.2%)**	8 (66.7%)	8 (25.8%)	6 (60%)
	(47.8%)						
WCC (x10 ⁹ /L)		8.2 (6.3-12.0)	7.1 (6.1-	8.8 (6.8-12.5)	12 (9.2-	8.2 (6.4-10.8)	8.3 (6.3-
			9.7)		20.3)		24.8)*
Neutrophils		6.4 (4.4-8.6)	5.5 (4.3-	6.7 (4.6-8.8)	9.7 (6.6-	6.5 (4.5-8.4)	5.8 (4.0-17.3)
(x10 ⁹ /L)			8.0)		12.2)		
(RP (mg/I))		103.0 (63.0-	86 0 (44 3-	116 0 (72 0-	50.5	98.0 (57.5-	139.0 (68.5-
		165.0)	158 3)	170.0)	(17 5-	155.0)	202.8)
		105.07	130.37	1/0.0/	147.3	155.07	202.07
NIR		5 / (3 8-10 8)	5 / (3 7-	15 (2 0-12 2)	10/13	63 (36-121)	A = (A = 0.11 = 5)
		5.4 (5.0 10.0)	75)	4.5 (5.5 15.5)	(6 7 22 5)	0.5 (5.0 12.1)	4.5 (4.0 11.5)
Moret NEWS2			6 (5 2 7 0)	60(4270)	(0.7-23.3)	60(4570)	70(7005)
				18.0 (0.0	4 (3.8-3.8)	70(50157.0)	17 5 (11 9
		14.5 (5.0-51.5)	<5 (<5-5.0)	18.0 (9.0-		7.0 (5.0-15.5)	-0.11) -71
(TIB/L)		202 0 /210 0	267.0	37.0) 408 5 (222 0		202.0 /242.5	37.0) ¹¹
D-dimer (ng/mL)		382.0 (218.0-	267.0	408.5 (233.0-		382.0 (242.5-	300.5 (182.8-
		829.5)	(201.0-	886.5)		825.0)	3003.3)
			572.0)	/			
Ferritin (µg/L)		1082 (428.3-	1169	995 (394.0-		1260 (548.3-	431 (371.0-
		1525.0)	(569.0-	2055.5)		1531.0)	2187.3)
			1377.0)				
Vitamin D		35.6 (23.0-	25.3 (18.3-	45.0 (25.6-	52.6	32.9 (21.4-	57.9 (29.6-
(nmol/L)		51.8)	36.0)	70.1)**	(45.4-	56.9)	86.5)**
					67.8)		
Dexamethasone		38 (92.6%)	10 (100%)	28 (90.3%)	10	28 (90%)	10 (100%)
					(83.3%)		
Admission							
4C		12 (9.0-14.0)			13 (11.0-	10.0 (6.5-	16 (13.3-
		,			14.8)*	13.0)	20.0)**
					- /	/	/
605A			1 (0 2 1 0)	1 (1 0 2 0)	1 (0 0 1 0)		
qSOFA		1 (1.0-1.5)	1 (0.3-1.0)	1 (1.0-2.0)	1 (0.0-1.0)	1 (0.5-1.0)	1.5 (1.0-2.0)
SOFA		1 (0.0-3.5)	0 (0.0-1.25)	2 (0.5-4.0)		1 (0.0-2.0)	4 (3.0-5.0)**
Length of stay		5.5 (3.0-12.0)	3.0 (2.0-	9.5 (4.3-		4.0 (2.3-12.0)	9.5 (6.3-12.0)
(days)			4.0)	12.0)*			
Presenting							
complaint							
Cough		31 (75.6%)	9 (90%)	22 (71.0%)		23 (74.2%)	8 (80%)
Anosmia		5 (12.2%)	2 (20%)	3 (9.7%)		5 (16.1%)	0 (0%)
Pyrexia		12 (29.2%)	5 (50%)	7 (22.6%)		11 (35.5%)	1 (10%)
Confusion		14 (34.1%)	0 (0%)	14 (14.2%)		6 (19.4%)	8 (80%)**

Belchamber et al. 2021

12

Myalgia	17 (41.5%)	7 (70%)	10 (32.6%)	14 (45.2%)	3 (30%)

399

400

401 Table 1. Patient demographic details. Data was collected at the time of recruitment. ± values 402 indicate SD. WCC- White cell count; CRP- C-reactive protein; NLR- neutrophil: lymphocyte 403 ratio; NEWS2- National Early Warning Score2; HS Troponin I- high sensitivity troponin I; 4C-404 4C Mortality Score for COVID-19; qSOFA- quick Sepsis-related Organ Failure Assessment; 405 SOFA- Sepsis-related Organ Failure Assessment. *<0.05, **< 0.001, *** <0.0001, normally 406 distributed results shown with mean ±SEM, not normally distributed results shown with 407 median (IQR Q1-Q3). Other diagnoses were included if they constituted significant impact on 408 quality of life or regular medication, included but not limited to: severe peripheral vascular 409 disease with active ulceration, dementia, chronic kidney disease, stroke, rheumatoid arthritis, 410 childhood polio, diverticulosis, obesity, alcohol liver disease.

411

Receptor		% expression				
	AMC N=22	COVID N=34	P value	AMC N=22	COVID N=34	P value
CD10	95.1 (7.72)	95.3 (13.6)	0.977	669 (697)	836 (518)	0.623
CD11b	81.0 (8.9)	67.8 (43.9)	*0.0229	343 (119)	40 (223)	*0.005
CD54	33.4 (35.3)	71.3 (21.2)	*<0.0001	21 (38)	73 (58)	*0.008
CD62L	19.8 (14.7)	31.0 (15.3)	*0.0096	62 (46)	94 (121)	0.379
CXCR2	100 (0.1)	100 (0.2)	0.119	2472 (1632)	2031 (1600)	0.153
CXCR4	96.6 (11.3)	96.7 (9.07)	0.508	2216 (4130)	1724 (4177)	0.552
CD66b	99.8 (0.5)	99.8 (0.3)	0.770	257 (213)	186 (161)	0.353
CD11c	99.7 (1.65)	99.9 (1.05)	0.101	220 (1274)	1148 (670)	*0.008
PD-L1	99.6 (40.4)	98 (27.9)	0.452	157 (166)	70 (132)	0.093

412

413 Table 2

414 Percentage of cells expressing, or MFI of isolated neutrophil cell surface markers measured

415 by flow cytometry in AMC (n=22) or COVID-19 patients (n=34). Data displayed as median

(IQR). Data analysed by individual Mann-Whitney test between AMC and COVID-19, with

Belchamber et al. 2021

significance shown in bold.

JH is s	supported by the National Institute for Health Research (NIHR) Surgical Reconstruct
and N	licrobiology Research Centre (SRMRC). The views expressed are those of the author
and n	ot necessarily those of the NIHR or the Department of Health and Social Care. Spe
thank	s to UK-Coronavirus immunology consortium.
Refer	ences
1.	Cucinotta, D. and M. Vanelli, <i>WHO Declares COVID-19 a Pandemic</i> . Acta Bion 2020. 91 (1): p. 157-160.
2.	WHO Coronavirus (COVID-19) Dashboard. [cited 2021 13th May]; Available fr
3.	Dorward, D.A., et al., <i>Tissue-Specific Immunopathology in Fatal COVID-19</i> . A
4.	Galani, I.E. and E. Andreakos, <i>Neutrophils in viral infections: Current concepts</i>
	caveats. J Leukoc Biol, 2015. 98(4): p. 557-64.
5.	Aulakh, G.K., Neutrophils in the lung: "the first responders". Cell and tissue resea
	2017. 371 : p. 577-588.
6.	Zhang, G., et al., Clinical features and short-term outcomes of 221 patients
	COVID-19 in Wuhan, China. J Clin Virol, 2020. 127: p. 104364.
7.	Printz, C., Poor COVID-19 outcomes and deaths linked to advanced age and
	existing conditions. Cancer, 2021. 127(4): p. 497.
8.	Chen, Y., et al., Aging in COVID-19: Vulnerability, immunity and intervention. Age
	Res Rev, 2021. 65: p. 101205.
9.	Sapey, E., et al., Phosphoinositide 3-kinase inhibition restores neutrophil accurac
	the elderly: toward targeted treatments for immunosenescence. Blood, 2014. 123(2
	239-248.
10.	Butcher, S.K., et al., Senescence in innate immune responses: reduced neutro
	phagocytic capacity and CD16 expression in elderly humans. J Leukoc Biol, 2
	70 (6): p. 881-6.
11.	Hazeldine, J., et al., Impaired neutrophil extracellular trap formation: a novel defendence
	the innate immune system of aged individuals. Aging Cell, 2014. 13(4): p. 690-8.
12.	Grudzinska, F.S., et al., Neutrophils in community-acquired pneumonia: parallel
	dysfunction at the extremes of age. Thorax, 2020. 75(2): p. 164-171.
13.	Patel, J.M., et al., Sepsis Induces a Dysregulated Neutrophil Phenotype Tha
	Associated with Increased Mortality. Mediators Inflamm, 2018. 2018: p. 4065362.
14.	Juss, J.K., et al., Acute Respiratory Distress Syndrome Neutrophils Have a Dist
	Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition. Am J Respir
	Care Med, 2016. 194 (8): p. 961-973.
15.	Sapey, E., et al., Pulmonary infections in the elderly lead to impaired neutro
	targetting, which is improved by simvastatin. American journal of respiratory
	critical care medicine, 2017. 196 (10).

Belchamber et al. 2021

463 464	16.	Greenwood, J., L. Steinman, and S.S. Zamvil, <i>Statin therapy and autoimmune disease: from protein prenylation to immunomodulation</i> . Nature reviews immunology, 2006. 6 :
465		p. 358-370.
466	17.	Sapey, E., et al., Simvastatin Improves Neutrophil Function and Clinical Outcomes in
467		Pneumonia. A Pilot Randomized Controlled Clinical Trial. Am J Respir Crit Care Med,
468		2019. 200 (10): p. 1282-1293.
469	18.	Drew, W., D.V. Wilson, and E. Sapey, Inflammation and neutrophil immunosenescence
470		in health and disease: Targeted treatments to improve clinical outcomes in the elderly.
471		Exp Gerontol, 2018. 105: p. 70-77.
472	19.	Rosales, C., Neutrophil: A Cell with Many Roles in Inflammation or Several Cell
473		<i>Types?</i> Front Physiol, 2018. 9: p. 113.
474	20.	Wang, J., et al., Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-
475		19. Front Immunol, 2020. 11: p. 2063.
476	21.	Aschenbrenner, A.C., et al., Disease severity-specific neutrophil signatures in blood
477		transcriptomes stratify COVID-19 patients. Genome Med, 2021. 13(1): p. 7.
478	22.	Schulte-Schrepping, J., et al., Severe COVID-19 Is Marked by a Dysregulated Myeloid
479		Cell Compartment. Cell, 2020. 182(6): p. 1419-1440.e23.
480	23.	Middleton, E.A., et al., Neutrophil extracellular traps contribute to immunothrombosis
481		in COVID-19 acute respiratory distress syndrome. Blood, 2020. 136(10): p. 1169-
482		1179.
483	24.	Skendros, P., et al., Complement and tissue factor-enriched neutrophil extracellular
484		traps are key drivers in COVID-19 immunothrombosis. J Clin Invest, 2020. 130(11): p.
485		6151-6157.
486	25.	Zuo, Y., et al., Neutrophil extracellular traps in COVID-19. JCI Insight, 2020. 5(11).
487	26.	Arcanjo, A., et al., The emerging role of neutrophil extracellular traps in severe acute
488		respiratory syndrome coronavirus 2 (COVID-19). Sci Rep, 2020. 10(1): p. 19630.
489	27.	Leppkes, M., et al., Vascular occlusion by neutrophil extracellular traps in COVID-19.
490		EBioMedicine, 2020. 58: p. 102925.
491	28.	Sapey, E., et al., Ethnicity and risk of death in patients hospitalised for COVID-19
492		infection in the UK: an observational cohort study in an urban catchment area. BMJ
493		OPen Respiratory Research, 2020. doi: bmjresp-2020-000644: p. 1 - 11.
494	29.	Walton, G.M., et al., <i>Repurposing treatments to enhance innate immunity. Can statins</i>
495		improve neutrophil functions and clinical outcomes in COPD? Journal of clinical
496		medicine, 2016. 5 (10).
497	30.	Knight, S.R., et al., Risk stratification of patients admitted to hospital with covid-19
498		using the ISARIC WHO Clinical Characterisation Protocol: development and
499		validation of the 4C Mortality Score. Bmj, 2020. 370 : p. m3339.
500	31.	COVID-19 rapid guideline: Managing COVID-19, N.I.f.H.a.C. Excellence, Editor.
501		2021.
502	32.	Ranieri, V.M., et al., Acute respiratory distress syndrome: the Berlin Definition. Jama,
503		2012. 307 (23): p. 2526-33.
504	33.	Liu, C.L., et al., Specific post-translational histone modifications of neutrophil
505		extracellular traps as immunogens and potential targets of lupus autoantibodies.
506		Arthritis Res Ther, 2012. 14(1): p. R25.
507	34.	Sinha, P., et al., Development and validation of parsimonious algorithms to classify
508		acute respiratory distress syndrome phenotypes: a secondary analysis of randomised
509	25	controlled trials. Lancet Respir Med, 2020. 8(3): p. 247-257.
510	35.	Injarabian, L., et al., Neutrophil Metabolic Shift during their Lifecycle: Impact on their
311		Survival and Activation. Int J Mol Sci, 2019. 21(1).

Belchamber et al. 2021

512 513	36.	Masso-Silva, J.A., et al., Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-19 patients: a case series and review of the
514		literature. Clin Infect Dis, 2021.
515	37.	Hazeldine, J., et al., Traumatic Injury and Exposure to Mitochondrial-Derived Damage
516	0,1	Associated Molecular Patterns Suppresses Neutrophil Extracellular Tran Formation
517		Front Immunol 2019 10: p 685
518	38	Vorobieva NV and BV Chernyak NETosis: Molecular Mechanisms Role in
510	50.	Physiology and Pathology Piochemistry (Mose) 2020 95 (10): p. 1178-1100
520	20	Mallroy, D.J. et al. Reduced deemviberuslages arrows gativity in response to high
520	39.	McIlloy, D.J., et al., <i>Keduceu deoxyribonucleuse enzyme uclivily in response io nign</i>
521		postinjury milochonarial DNA concentration provides a therapeutic target for Systemic
522	40	Inflammatory Response Syndrome. J Irauma Acute Care Surg, 2018. 85(2): p. 354-358.
523	40.	Feldman, C. and R. Anderson, <i>The role of co-infections and secondary injections in</i>
524		patients with COVID-19. Pneumonia (Nathan), 2021. 13(1): p. 5.
525	41.	Buehler, P.K., et al., Bacterial pulmonary superinfections are associated with
526		unfavourable outcomes in critically ill COVID-19 patients. medRxiv, 2020.
527	42.	Zhu, X., et al., Co-infection with respiratory pathogens among COVID-2019 cases.
528		Virus Res, 2020. 285 : p. 198005.
529	43.	Nguyen, G.T., E.R. Green, and J. Mecsas, Neutrophils to the ROScue: Mechanisms of
530		NADPH Oxidase Activation and Bacterial Resistance. Front Cell Infect Microbiol,
531		2017. 7 : p. 373.
532	44.	Veras, F.P., et al., SARS-CoV-2-triggered neutrophil extracellular trans mediate
533		COVID-19 nathology J Exp Med. 2020. 217(12).
534	45	Messner C B et al Ultra-High-Throughput Clinical Proteomics Reveals Classifiers
535	10.	of COVID-19 Infection Cell Syst 2020 11(1): n 11-24 e4
536	46	Overmuer K A et al Large-Scale Multi-omic Analysis of COVID-10 Savarity Cell
530	т 0.	Syst 2021 $12(1)$: p 22.40 o7
537	47	Syst, 2021. 12(1). p. 23-40.07.
330 520	4/.	Shen, B., et al., Proteomic and Metabolomic Characterization of COVID-19 Patient
539	40	Sera. Cell, 2020. $182(1)$: p. 59-72.e15.
540	48.	Andrew, N. and R.H. Insall, <i>Chemotaxis in shallow gradients is mediated</i>
541		independently of PtdIns 3-kinase by biased choices between random protrusions. Nat
542		Cell Biol, 2007. 9(2): p. 193-200.
543	49.	Lee, W.L., R.E. Harrison, and S. Grinstein, <i>Phagocytosis by neutrophils</i> . Microbes
544		Infect, 2003. 5 (14): p. 1299-306.
545	50.	Stephens, L., C. Ellson, and P. Hawkins, Roles of PI3Ks in leukocyte chemotaxis and
546		phagocytosis. Curr Opin Cell Biol, 2002. 14(2): p. 203-13.
547	51.	Papayannopoulos, V., Neutrophil extracellular traps in immunity and disease. Nature
548		reviews immunology, 2018. 18 : p. 134-147.
549	52.	Erpenbeck, L., et al., Effect of Adhesion and Substrate Elasticity on Neutrophil
550		Extracellular Trap Formation. Front Immunol, 2019. 10: p. 2320.
551	53.	DeSouza-Vieira, T., et al., Neutrophil extracellular traps release induced by
552		Leishmania: role of PI3Ky, ERK, PI3Ko, PKC, and $[Ca2+1]$, J Leukoc Biol. 2016.
553		100 (4): n. 801-810.
554	54	Lewis SM et al Expression of CD11c and FMR? on neutrophils: notential
555	51.	diagnostic biomarkers for sensis and systemic inflammation Clin Exp Immunol 2015
556		$182(2) \cdot n = 184-94$
557	55	Marini Ω et al. Matura $CD10(+)$ and immature $CD10()$ neutrophils present in G
559	55.	CSE tragted denorg dignlaw enposite effects on T cells Plead 2017 120 (10): p 1242
550		CSF-treated donors display opposite effects on 1 cetts. Blood, 2017. 129(10). p. 1545-
559		1550.

Belchamber et al. 2021

16

- 560 56. Martin, C., et al., Chemokines acting via CXCR2 and CXCR4 control the release of
 561 *neutrophils from the bone marrow and their return following senescence*. Immunity,
 562 2003. 19(4): p. 583-93.
- 563 57. Wilk, A.J., et al., A single-cell atlas of the peripheral immune response in patients with
 564 severe COVID-19. Nat Med, 2020. 26(7): p. 1070-1076.
- 565 58. Buckley, C.D., et al., Identification of a phenotypically and functionally distinct
 566 population of long-lived neutrophils in a model of reverse endothelial migration. J
 567 Leukoc Biol, 2006. 79(2): p. 303-11.
- 568 59. Metzemaekers, M., et al., *Kinetics of peripheral blood neutrophils in severe* 569 *coronavirus disease 2019.* Clin Transl Immunology, 2021. **10**(4): p. e1271.
- 570 60. Carvelli, J., et al., Association of COVID-19 inflammation with activation of the C5a571 C5aR1 axis. Nature, 2020. 588(7836): p. 146-150.
- 572 61. Shambat, S.M., et al., Neutrophil and monocyte dysfunctional effector response
 573 towards bacterial challenge in critically-ill COVID-19 patients. bioRxiv, 2020.
- 574 62. Blanco-Melo, D., et al., *Imbalanced Host Response to SARS-CoV-2 Drives* 575 *Development of COVID-19.* Cell, 2020. **181**(5): p. 1036-1045.e9.
- 576 63. Chalmers, J.D., et al., *Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in*577 *Bronchiectasis.* N Engl J Med, 2020. 383(22): p. 2127-2137.
- 578 64. Zuo, Y., et al., *Neutrophil extracellular traps and thrombosis in COVID-19*. J Thromb
 579 Thrombolysis, 2021. 51(2): p. 446-453.
- 580 581
- 582

583 Figure 1 – Patient recruitment

584 45 patients with COVID-19 were recruited from the Queen Elizabeth Hospital Birmingham, 585 alongside 23 age matched controls. Blood was taken, and neutrophils isolated.

586

587 Figure 2 – Neutrophil functional responses in COVID-19

588 A. Neutrophil transmigration towards IL-8. Data shows fold change in neutrophils migrated to 589 CXCL-8 compared to vehicle control. AMC, n=18; COVID-19 patients n=28. *p=0.0397, Mann-590 Whitney U test. B. Neutrophil phagocytosis of opsonised S. pneumoniae following a 30-591 minute incubation. Data shows MFI of positive neutrophils. *p=0.0236 Mann-Whitney U test 592 between AMC (n=24) and COVID-19 patients (n=30). C. Cytoplasmic ROS levels measured in 593 neutrophils at baseline (0 minutes) and after phagocytosis. Data were analysed by two-way 594 ANOVA *p<0.0235, ***p=0.0005 between time 0 and 30 minutes. D. Nuclear/mitochondrial 595 ROS levels in neutrophils at baseline (0 minutes) and after phagocytosis. Data were analysed 596 by two-way ANOVA and post-hoc test *p<0.0001 between time 0 and 30 minutes. ### 597 p<0.0001 between AMC and COVID-19 patients.

598

599 Figure 3 - NETosis in COVID-19.

600 A. NET release by neutrophils stimulated with PMA for 3 hours, measured as absorbance of 601 cfDNA stained with Sytox green. Data shows fold change in absorbance of PMA stimulated 602 neutrophils compared to vehicle control. Data analysed by Mann-Whitney U test between AMC (n=23) and COVID-19 patients (n=33), *p=0.0366. B. Comparison of NET release by 603 604 activated neutrophils in patients with low 4C (n=8) or high 4C (N=26) score. Data analysed by 605 Mann-Whitney U test, *p=0.0118. C. Plasma cell free DNA levels measured by flurometry in 606 AMC (n=23) and COVID-19 patients (n-41). Data analysed by Mann-Whitney U test, 607 *p=0.0153. D. Comparison of cfDNA levels measured by flurometry in COVID-19 (N=10) on

Belchamber et al. 2021

17

day 1 and on day 3-5. Data analysed by Wilcoxon test. *p=0.0186. E. % DNA degradation by
 serum NETs in AMC (n=23) and COVID-19 (n=41). Data analysed by Mann-Whitney U test
 ***p<0.0001.

611

612 Figure 4 – Neutrophil phenotype in COVID-19

Expression of cell surface markers on neutrophils measured by flow cytometry. Data shows
MFI of CD11b (A, p=0.0003)), CD11c (B, p=0.0008), % expression of CD54 (C, p=<0.0001) and
MFI of CD54 (D, p=0.0008) in AMC (n=22) and COVID-19 patients (n=34). Data were analysed
by Mann-Whitney U test. Expression of CXCR2 (E, p=0.0322), CXCR4 (F, p=0.0273) and %
expression of CD54 (G, p=0.0420) on COVID-19 neutrophils on day 1 or follow up (day 3-5).
Data are expressed as individual points, analyzed by Wilcoxon test (n=11).

- 619
- 620

621 Figure 5 – Plasma cytokine levels in COVID-19

Plasma concentrations of A. IL-6 (A, p=0.009), VEGF (B, p<0.0001), sTNFRI (C, p<0.0001), GM-
CSF (D, p=0.3375) and MPO (E, p<0.0001) in AMC (n=24) and COVID-19 patients (N=41). Data
analysed by Mann-Whitney U test.

625

626 Figure 6 – Summary of results

627 Compared to AMC, neutrophils isolated from non-ICU COVID-19 patients demonstrate 628 increased migration, impaired phagocytosis and reduced nuclear/mitochondrial ROS 629 generation. COVID-19 neutrophils have altered phenotype, displaying increased expression 620 of minority and control of the set of the

630 of migration markers CD54 and CD11c. COVID-19 patients also display elevated NETosis, both

631 ex vivo and in the circulation, and elevated pro-inflammatory cytokines. This contributes to

- 632 disease pathogenesis in COVID-19.
- 633

Belchamber et al. 2021



Belchamber et al. 2021



Belchamber et al. 2021



Belchamber et al. 2021



Belchamber et al. 2021



Belchamber et al. 2021



831 832 Figure 6